VIDEO: Risankizumab improves psoriasis after poor response to secukinumab, ixekizumab

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses the benefits of switching patients with psoriasis to risankizumab after suboptimal response from secukinumab or ixekizumab treatment.

The research, which was presented by Richard B. Warren, BSc, MBChB, MRCP, PhD, at the American Academy of Dermatology Annual Meeting, showed that after 16 weeks, 56% of patients reached a Static Physician Global Assessment score of 0 or 1, defined as clear or almost clear skin. Further, at 52 weeks, 63% of patients attained this same endpoint.

This research supports the use of risankizumab to treat plaque psoriasis even in patients with other conditions or in those who had little success with other therapies, according to Wu.

“This seems to show that if a patient fails one of these, either secukinumab or ixekizumab, it may be helpful if you switch these patients to another class — namely risankizumab — because the majority of these patients will reach clear or almost clear after 16 weeks and after 52 weeks,” Wu, a voluntary associate professor in the department of dermatology at University of Miami Miller School of Medicine, said.

Reference:

• Warren RB. Efficacy and safety after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans.